Protocol for qRT-PCR analysis from formalin fixed paraffin embedded tissue sections from diffuse large b-cell lymphoma: Validation of the six-gene predictor score

As a part of an international study on the molecular analysis of Diffuse Large B-cell Lymphoma (DLBCL), a robust protocol for gene expression analysis from RNA extraction to qRT-PCR using Formalin Fixed Paraffin Embedded tissues was developed. Here a study was conducted to define a strategy to valid...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncotarget 2016-12, Vol.7 (50), p.83319-83329
Hauptverfasser: Tekin, Nilgun, Omidvar, Nader, Morris, Tim Peter, Conget, Paulette, Bruna, Flavia, Timar, Botond, Gagyi, Eva, Basak, Ranjan, Naik, Omkar, Auewarakul, Chirayu, Sritana, Narongrit, Levy, Debora, Cerci, Juliano Julio, Bydlowski, Sergio Paulo, Pereira, Juliana, Dimamay, Mark Pierre, Natividad, Filipinas, Chung, June-Key, Belder, Nevin, Kuzu, Isinsu, Paez, Diana, Dondi, Maurizio, Carr, Robert, Ozdag, Hilal, Padua, Rose Ann
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:As a part of an international study on the molecular analysis of Diffuse Large B-cell Lymphoma (DLBCL), a robust protocol for gene expression analysis from RNA extraction to qRT-PCR using Formalin Fixed Paraffin Embedded tissues was developed. Here a study was conducted to define a strategy to validate the previously reported 6-gene (LMO2, BCL6, FN1, CCND2, SCYA3 and BCL2) model as predictor of prognosis in DLBCL. To avoid variation, all samples were tested in a single centre and single platform. This study comprised 8 countries (Brazil, Chile, Hungary, India, Philippines, S. Korea, Thailand and Turkey). Using the Kaplan-Meier and log rank test on patients (n=162) and two mortality risk groups (with those above and below the mean representing high and low risk groups) confirmed that the 6-gene predictor score correlates significantly with overall survival (OS, p
ISSN:1949-2553
1949-2553
DOI:10.18632/oncotarget.13066